Douglas Adkins is an Oncology physician affiliated with Washington University in St. Louis. OpenAlex indexes 41 publications with 697 citations (h-index 9); ClinicalTrials.gov lists 21 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4500 Forest Park Ave
Div Im Medical Oncology, Ste 1b
Saint Louis, MO 631082114
Telephone
314-747-1171Registry record last updated 12 May 2026.
Clinical trials
- CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma
Sponsor: Washington University School of Medicine
- Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: Washington University School of Medicine
- 5-Fluorouracil Response and Optimization STudy (The FROST Trial)
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202519 payments$19,262openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year20257 payments
- AstraZeneca UK LimitedProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
37%Corticosteroid37%Dexamethasone sodium phosphate89%Dexamethasone11%Part D + Part B≥31 patientsMetabolism & gastrointestinal
25%Serotonin-3 Receptor Antagonist17.5%Palonosetron hcl100%Part B, office-administered≥21 patientsCorticosteroid6.8%Prednisone100%Part D≥23 patients+ 1 more class in this area
Nervous system
14.5%Opioid Agonist8.9%Oxycodone Hcl47%Fentanyl23%Morphine Sulfate11%Morphine Sulfate Er10%Methadone Hcl10%Part D<11 patientsPhenothiazine3.4%Prochlorperazine Maleate100%Part D≥36 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Ley, MD
Washington University in St. Louis
David Gutmann, MD
Washington University in St. Louis
Randall Bateman, MD
Washington University in St. Louis
Victoria Fraser, MD
Washington University in St. Louis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”